Insider · SEC Form 4 filer

Fairmount Funds Management LLC

Companies

Where they file as an insider

Apogee Therapeutics (APGE) Director Latest filing Sep 3, 2026
Spyre Therapeutics (SYRE) Director Latest filing Jun 23, 2026
Cogent Biosciences (COGT) Director Latest filing Mar 31, 2026
Viridian Therapeutics (VRDN) Director, 10% owner Latest filing Jun 10, 2025
Dianthus Therapeutics (DNTH) Director, 10% owner Latest filing Jan 22, 2024

Track record

Did their buys beat the typical stock?

Open-market buys1
Quarters checked 6 months later1
Beat the typical stock —
Quarters too new to check0

Too soon to tell. 1 quarter has finished so far. We show a record once 3 have.

Cogent Biosciences (COGT) Bought Jul 10, 2025 · $25M · 2.78M shares Beat typical Sep 30, 2025 $14.36 → Mar 31, 2026 $38.49 · +168.0% (typical stock −3.4%)

Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.

Past results. This is data, not advice.

Where this data comes from. Insider trades, fund holdings, activist stakes and company results come from public SEC EDGAR filings (Forms 4, 13F, 13D/13G, 10-Q and 8-K). Congress trades come from the STOCK Act reports members file with the House Clerk and the Senate. Daily closing prices come from post-no-preference/stocks on DoltHub, a community-run database shared under CC BY-SA 4.0; the prices we show stay under that license. They are each day's close, not live or official exchange prices.

This is data, not investment advice. About StockToast · Your watchlist